Compass Therapeutics Inc. (CMPX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $139.35M
Last updated: Nov 17, 2026 at 11:04 AM ET
Compass Therapeutics Inc. (CMPX) Stock Forecast
Analysts expect Compass Therapeutics (CMPX) to earn -$0.49 per share in the fiscal year ending Dec 31, 2026. Of 15 analysts, 12 rate the stock Buy or Strong Buy, 3 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 3 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 15 ratings average 2.07, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 80% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 13.3% |
| Buy | 10 | 66.7% |
| Hold | 3 | 20.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 15
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss.
- Fiscal year ending Dec 31, 2026
- -$0.49
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$0.55
- EPS consensus, revenue $4.71M
- Next report
- Mar 3, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.49 | -$0.52 to -$0.44 | 8 | N/A | N/A | 14 |
| Dec 31, 2027 | -$0.55 | -$0.66 to -$0.38 | 10 | $4.71M | N/A | 13 |
Quarterly Estimates
The EPS consensus rises from -$0.15 for the quarter ending Dec 31, 2026 to -$0.13 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.15 | -$0.17 to -$0.13 | 17 |
| Mar 31, 2027 | -$0.13 | -$0.16 to -$0.11 | 6 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 8 upward and 7 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 3 | 0 |
| Fiscal year ending Dec 31, 2027 | 2 | 7 |
| Quarter ending Mar 31, 2027 | 3 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.48.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.49 | -$0.48 | -$0.48 | -$0.49 | -$0.48 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.55 | -$0.54 | -$0.54 | -$0.54 | -$0.52 | N/A |
| Quarter ending Mar 31, 2027 | -$0.13 | -$0.13 | -$0.13 | -$0.15 | -$0.14 | N/A |
Frequently Asked Questions About CMPX
What is the CMPX stock forecast?
Consensus analyst estimates put Compass Therapeutics's EPS at -$0.49 for the fiscal year ending Dec 31, 2026. The consensus rating from 15 analysts is Buy.
How do analysts rate CMPX stock?
Of 15 analysts covering Compass Therapeutics, 2 rate it Strong Buy, 10 Buy, 3 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from CMPX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.49, with estimates from -$0.52 to -$0.44 from 8 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.55, with estimates from -$0.66 to -$0.38 from 10 analysts.
What revenue do analysts expect from Compass Therapeutics next year?
For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $4.71M.
How many analysts cover CMPX?
15 analysts rate Compass Therapeutics stock, and 8 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
CMPX pages: Overview, Earnings, Forecast, Financials, Competitors